VIDO awarded U.S. contract for its Vaccine Development Centre
Nov 21, 2023 - VIDO has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract by the United States’ National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
VIDO’s first Animal Health Summit brings animal health stakeholders together to prepare for foot and mouth disease
Oct 30, 2023 - On August 24th, VIDO hosted a half-day summit on foot-and-mouth disease (FMD). Our biannual Animal Health Summit will bring together stakeholders to facilitate knowledge exchange and preparedness on a topic of interest.
VIDO and Pirbright expand collaboration to advance vaccine manufacturing
Oct 27, 2023 - VIDO has signed a memorandum of understanding (MOU) with the Centre for Veterinary Vaccine Innovation and Manufacturing at the Pirbright Institute in the UK. The MOU allows for expanded animal health collaborations and training.
USask’s VIDO selected for CEPI’s international research network
Sep 26, 2023 - VIDO has signed an agreement to join the Coalition for Epidemic Preparedness Innovations’ (CEPI) preclinical research network—the only organization in Canada and the ninth in the world selected for this research network to date.
VIDO receives significant CIHR support for research into emerging coronaviruses
Aug 2, 2023 - VIDO scientists have received support from the Canadian Institutes of Health Research’s Spring 2023 competition.
New funding to advance Canada’s beef sector
Jul 25, 2023 - Dr. Antonio Facciuolo has new support to develop a vaccine against Johne’s disease—a chronic intestinal disease of cattle that is significant to both the beef and dairy industry.
VIDO scientists strengthen mpox preparedness
May 24, 2023 - VIDO scientists have received >$1-million in total funding to study mpox (formerly known as monkeypox) from the Canadian Institutes of Health Research “Team Grant: Mpox (monkeypox) and zoonotic threats.”
VIDO led technology a key part of the vaccine protecting koalas from chlamydia
May 19, 2023 - An adjuvant developed by VIDO and partners is a key component in a vaccine to protect koalas from chlamydia. The adjuvant improves the effectiveness of the vaccine by improving the koala immune response.
VIDO and VFI collaborate to strengthen pandemic preparedness
Apr 28, 2023 - VIDO and the Vaccine Formulation Institute (VFI) sign collaborative research agreement to help drive joint vaccine development and support a rapid and unified response to future pandemics.
VIDO scientists receive leadership awards for excellence in vaccine research
Apr 27, 2023 - Drs. Darryl Falzarano and Alyson Kelvin have been recognized by the Canadian Institutes of Health Research (CIHR) for their international leadership in vaccine research for infectious diseases.
VIDO partners with four research hubs to strengthen Canada’s infectious disease preparedness
Apr 11, 2023 - The hubs will help accelerate the research, development, and translation of vaccines therapeutics and diagnostics into commercially viable products and processes. They will also expand skilled talent by supporting training and development.
The avian influenza outbreak: what you need to know
Mar 8, 2023 - Parts of North America, Europe, Asia, and Africa are currently experiencing outbreaks of H5N1 bird flu. H5N1 is present in all major flyways globally, with millions of affected birds including over 7 million in Canada and 500,000 in Saskatchewan.
Integrating field and laboratory studies to better predict the next emerging zoonotic pathogen
Mar 6, 2023 - The COVID-19 pandemic, and discovery of SARS-CoV-2–like viruses in Rhinolophus bats, reinforced the need to identify wildlife sources of zoonotic pathogens and to forecast where and when ‘spillover’ to humans is likely.
CIHR supports research targeting high impact infectious diseases
Feb 17, 2023 - VIDO’s scientists, Drs Neeraj Dhar and Alyson Kelvin, were awarded support from the Canadian Institutes of Health Research Project Grant Fall 2022 Competition to target priority human diseases.
VIDO first non-U.S. organization invited to join high containment network
Feb 15, 2023 - VIDO has been accepted as the first and only international organization in the Research Alliance for Veterinary Science and Biodefense BSL-3 Network—a partnership of 18 U.S. based large biocontainment facilities focused on veterinary infectious diseases.
Leaders in discovery: five USask researchers honoured with top provincial health awards
Jan 26, 2023 - Dr. Volker Gerdts, director and CEO of VIDO and professor in the Western College of Veterinary Medicine at the University of Saskatchewan, has been recognized with an Achievement Award by the Saskatchewan Health Research Foundation (SHRF).
VIDO awarded over a million dollars for innovative research projects
Jan 26, 2023 - Five VIDO scientists were awarded over $1 million in total from Saskatchewan’s Agriculture Development Fund (ADF)—a program jointly funded by the provincial and federal governments.